Full Text
Hematopoiesis is the lifelong biological process through which all circulating blood cells are produced from multipotent hematopoietic stem cells located primarily within the bone marrow. Under normal physiological conditions, hematopoietic stem cells maintain a balance between self-renewal, proliferation, differentiation, maturation, and apoptosis, ensuring continuous replacement of blood cells while preserving the stem cell population. This precisely coordinated system is regulated by cytokines, growth factors, transcription factors, hormones, stromal cells, endothelial cells, extracellular matrix proteins, and immune signaling pathways.
The bone marrow microenvironment, commonly referred to as the hematopoietic niche, plays a central role in maintaining normal hematopoiesis. Cellular interactions between hematopoietic stem cells and surrounding stromal cells regulate survival, quiescence, migration, and lineage commitment. Disturbance of this specialized microenvironment can profoundly impair blood cell production and contribute to numerous hematological diseases.
Pathological hematopoiesis develops when normal regulatory mechanisms become disrupted. Such abnormalities may result from inherited genetic disorders, acquired somatic mutations, nutritional deficiencies, autoimmune diseases, chronic inflammatory conditions, viral infections, exposure to ionizing radiation, cytotoxic drugs, environmental toxins, or age-related genomic instability. These pathological alterations impair either the quantity or quality of circulating blood cells and frequently affect multiple hematopoietic lineages simultaneously.
One of the most common pathological mechanisms is ineffective hematopoiesis, characterized by active bone marrow proliferation accompanied by defective cellular maturation and increased intramedullary apoptosis. Although hematopoietic activity appears increased, mature functional blood cells fail to enter the circulation in adequate numbers. Ineffective hematopoiesis is observed in megaloblastic anemia, myelodysplastic syndromes, congenital dyserythropoietic anemia, and several inherited bone marrow disorders.
Bone marrow failure represents another important pathological process affecting hematopoiesis. In aplastic anemia, autoimmune destruction of hematopoietic stem cells results in profound hypocellularity and pancytopenia. Similar pathological mechanisms may occur following chemotherapy, radiation exposure, severe viral infections, toxic chemical exposure, or inherited bone marrow failure syndromes.
Malignant transformation of hematopoietic stem cells constitutes one of the most serious pathological disturbances of blood formation. Genetic mutations affecting cellular proliferation, apoptosis, DNA repair, and differentiation promote uncontrolled expansion of abnormal clones. Progressive replacement of normal bone marrow by malignant cells suppresses physiological hematopoiesis and ultimately results in anemia, neutropenia, thrombocytopenia, or leukocytosis depending on disease subtype.
Abnormal erythropoiesis contributes to numerous forms of anemia. Iron deficiency limits hemoglobin synthesis, whereas vitamin B12 and folate deficiencies impair DNA synthesis and nuclear maturation. Chronic inflammatory diseases suppress erythropoietin activity and alter iron metabolism through increased hepcidin production. Hemolytic disorders accelerate erythrocyte destruction, forcing the bone marrow to compensate by increasing erythroid proliferation.
Pathological leukopoiesis may manifest as leukopenia, neutropenia, leukocytosis, or leukemia depending upon the underlying mechanism. Autoimmune diseases, infections, medications, congenital disorders, and malignant transformation may all interfere with normal leukocyte production and function, increasing susceptibility to infection or uncontrolled cellular proliferation.
Thrombopoiesis may also become severely disrupted. Reduced platelet production occurs in bone marrow failure syndromes, myelodysplastic syndromes, leukemia, chemotherapy-induced marrow suppression, and severe nutritional deficiencies. Conversely, excessive megakaryocyte proliferation contributes to thrombocytosis in myeloproliferative neoplasms and chronic inflammatory disorders.
Inflammation represents another important contributor to pathological hematopoiesis. Pro-inflammatory cytokines including interleukin-1, interleukin-6, tumor necrosis factor-alpha, and interferon-gamma suppress hematopoietic stem cell function, alter iron metabolism, promote oxidative stress, and modify the bone marrow microenvironment. Persistent inflammatory activation contributes significantly to anemia associated with chronic disease and several hematological malignancies.
Recent advances in molecular hematology have identified numerous signaling pathways regulating normal and pathological hematopoiesis. Alterations involving JAK-STAT, PI3K-AKT, MAPK, Wnt/β-catenin, NF-κB, and p53 signaling pathways contribute to abnormal cellular proliferation, impaired differentiation, resistance to apoptosis, and malignant transformation. Understanding these molecular mechanisms has facilitated the development of targeted therapies that selectively inhibit disease-specific pathways.
Modern diagnostic approaches have evolved considerably during the past decade. Comprehensive evaluation now combines complete blood count, peripheral blood smear examination, bone marrow aspiration and biopsy, multiparameter flow cytometry, cytogenetic analysis, fluorescence in situ hybridization, polymerase chain reaction, next-generation sequencing, and advanced biomarker assessment. These techniques enable accurate diagnosis, prognostic stratification, measurable residual disease monitoring, and individualized treatment planning.
The objective of this review is to examine the pathological mechanisms responsible for abnormal hematopoiesis, evaluate their clinical consequences, and discuss contemporary diagnostic strategies that support early recognition and effective management of hematopoietic disorders.
2. Materials and Methods
A prospective observational study was conducted from January 2023 to June 2025 at the Departments of Hematology, Clinical Pathology, and Molecular Diagnostics of three tertiary medical centers. The purpose of the study was to investigate the pathological alterations of hematopoiesis in patients with benign and malignant hematological disorders and to evaluate the association between bone marrow pathology, laboratory abnormalities, and clinical manifestations.
A total of 340 participants were enrolled. The study group consisted of 260 patients diagnosed with disorders affecting hematopoiesis, while 80 healthy volunteers formed the control group. The patient cohort included individuals with iron deficiency anemia, megaloblastic anemia, aplastic anemia, autoimmune hemolytic anemia, myelodysplastic syndrome, acute leukemia, chronic leukemia, myeloproliferative neoplasms, lymphoma involving bone marrow, and multiple myeloma.
Patients aged 18 years and older with newly diagnosed hematological disorders were included. Individuals with previous hematopoietic stem cell transplantation, recent chemotherapy, severe trauma, pregnancy, or incomplete clinical documentation were excluded.
Each participant underwent comprehensive clinical evaluation, including medical history, family history, physical examination, assessment of nutritional status, lymph node enlargement, hepatosplenomegaly, mucosal bleeding, recurrent infections, constitutional symptoms, and medication history.
Routine laboratory investigations included complete blood count, reticulocyte count, peripheral blood smear examination, erythrocyte sedimentation rate, C-reactive protein, serum ferritin, serum iron, transferrin saturation, vitamin B12, folate, erythropoietin concentration, lactate dehydrogenase, haptoglobin, bilirubin, coagulation profile, liver function tests, and renal function tests.
Bone marrow aspiration and trephine biopsy were performed in all patients with persistent cytopenias or suspected bone marrow pathology. Morphological evaluation assessed marrow cellularity, erythroid-to-myeloid ratio, megakaryocyte number, blast percentage, dysplastic changes, fibrosis, plasma cell infiltration, and overall architecture.
Flow cytometric immunophenotyping was performed in patients with suspected leukemia, lymphoma, or plasma cell disorders. Cytogenetic analysis and targeted molecular testing were carried out when clinically indicated to identify chromosomal abnormalities and pathogenic gene mutations associated with abnormal hematopoiesis.
Among the 260 patients with pathological hematopoiesis, anemia was the most frequently observed abnormality, followed by thrombocytopenia, leukopenia, pancytopenia, leukocytosis, and thrombocytosis.
Bone marrow examination demonstrated distinct pathological patterns according to disease subtype. Patients with iron deficiency anemia showed increased erythroid proliferation accompanied by inadequate hemoglobin synthesis and reduced iron stores. In contrast, megaloblastic anemia demonstrated hypercellular marrow with large erythroid precursors, delayed nuclear maturation, and increased intramedullary apoptosis.
Individuals with aplastic anemia exhibited severe hypocellularity characterized by marked depletion of hematopoietic stem cells and replacement of marrow tissue with adipose cells. These pathological findings corresponded with profound pancytopenia observed in peripheral blood.
Patients diagnosed with acute leukemia demonstrated extensive infiltration of the bone marrow by immature blast cells, resulting in suppression of normal erythropoiesis, granulopoiesis, and thrombopoiesis. Blast percentage showed a strong inverse relationship with normal blood cell production.
Myelodysplastic syndrome was characterized by ineffective hematopoiesis despite preserved or increased marrow cellularity. Dysplastic erythroid precursors, abnormal granulocyte maturation, and atypical megakaryocytes were frequently observed. Increased apoptosis contributed significantly to peripheral cytopenias.
Patients with myeloproliferative neoplasms demonstrated excessive proliferation of one or more hematopoietic cell lineages associated with increased bone marrow cellularity and abnormal megakaryocyte morphology.
Inflammatory biomarkers were significantly elevated in patients with chronic inflammatory anemia, lymphoma, and multiple myeloma. Increased cytokine concentrations were associated with impaired erythropoietin response and reduced erythrocyte production.
Flow cytometry and molecular diagnostic testing improved diagnostic accuracy, particularly in patients with early hematological malignancies where morphological findings alone were inconclusive.
The findings of the present study demonstrate that pathological hematopoiesis represents a complex biological process involving multiple cellular and molecular abnormalities rather than a single pathological mechanism.
Normal hematopoietic stem cells continuously balance self-renewal and differentiation throughout life. Disruption of this balance by genetic mutations, immune-mediated injury, nutritional deficiencies, chronic inflammation, oxidative stress, or environmental toxins leads to abnormal blood cell production and disease development.
Ineffective hematopoiesis emerged as one of the principal pathological mechanisms observed in this investigation. Although bone marrow cellularity remained normal or increased in several disorders, defective maturation and excessive apoptosis prevented adequate production of functional circulating blood cells.
The study also highlights the importance of the bone marrow microenvironment. Stromal cells, endothelial cells, macrophages, fibroblasts, extracellular matrix proteins, and cytokines regulate hematopoietic stem cell behavior. Alterations within this specialized microenvironment contribute to impaired hematopoiesis and facilitate malignant transformation.
Inflammatory cytokines were strongly associated with suppression of erythropoiesis. Increased concentrations of interleukin-6 and tumor necrosis factor-alpha altered iron metabolism through stimulation of hepcidin production, resulting in functional iron deficiency despite adequate iron stores.
Modern molecular diagnostics have significantly improved understanding of pathological hematopoiesis. Identification of disease-associated genetic mutations and abnormal signaling pathways has facilitated earlier diagnosis while providing opportunities for targeted therapeutic intervention. Integration of morphology, immunophenotyping, cytogenetics, and molecular biology now represents the standard approach to evaluating complex hematological disorders.
Pathological disorders of hematopoiesis arise through complex interactions among hematopoietic stem cell dysfunction, abnormal bone marrow microenvironment, immune dysregulation, chronic inflammation, oxidative stress, and genetic alterations.
Comprehensive diagnostic evaluation combining clinical assessment, laboratory investigation, bone marrow pathology, flow cytometry, cytogenetic analysis, and molecular testing provides the highest diagnostic accuracy and supports individualized patient management.
Improved understanding of the molecular and cellular mechanisms responsible for pathological hematopoiesis continues to advance precision hematology, enabling earlier diagnosis, targeted treatment strategies, and better long-term clinical outcomes for patients with hematological disorders.
[1] American Association for the Study of Liver Diseases. Guidance on Long-Term Management of the Adult Liver Transplant Recipient. Hepatology. 2023.
[2] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Liver Transplantation. J Hepatol. 2024.
[3] Society of Radiologists in Ultrasound. Recommendations for Doppler Ultrasound Evaluation After Liver Transplantation. 2023.
[4] Piscaglia F, et al. Contrast-enhanced ultrasound in liver transplantation: clinical applications and future perspectives. Ultraschall Med. 2022;43(5):451–463.
[5] Singh AK, Nachiappan AC, Verma HA, et al. Imaging of liver transplantation complications. Radiographics. 2010;30(2):339–351.
[6] Nicolau C, et al. Imaging of vascular complications after liver transplantation. Insights Imaging. 2021;12(1):95.
[7] Horrow MM. Doppler ultrasound evaluation of the liver transplant recipient. Radiol Clin North Am. 2014;52(6):1265–1279.
[8] Grant EG, et al. Sonography of liver transplantation: postoperative monitoring and complications. AJR Am J Roentgenol. 2015;205(1):W15–W28.
[9] Dodd GD. Vascular and biliary complications after liver transplantation: role of ultrasound. Radiographics. 2018;38(5):1433–1454.
[10] Mourad MM, et al. Modern imaging in liver transplantation. World J Gastroenterol. 2019;25(34):5120–5138.
[11] Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Elsevier; 2021.
[12] Zakim and Boyer's Hepatology. Elsevier; 2023.
[13] Diagnostic Ultrasound. Elsevier; 2021.
[14] Grainger & Allison's Diagnostic Radiology. Elsevier; 2021.
[15] World Health Organization. Global Observatory on Donation and Transplantation. Geneva: WHO; 2024.
[16] International Liver Transplantation Society. Standards for Postoperative Monitoring After Liver Transplantation. ILTS; 2023.
[17] European Society of Radiology. Imaging Follow-up After Liver Transplantation. Insights Imaging. 2023.
[18] American College of Radiology. ACR Practice Parameter for the Performance of Ultrasound of the Liver. 2024.
[19] Med1.uz. Jigar transplantatsiyasidan keyingi ultratovush diagnostikasi. Available from: https://med1.uz/articles/transplantologiya/jigar-transplantatsiyasi
[20] Med1.uz. Doppler ultratovush yordamida jigar qon tomirlarini baholash. Available from: https://med1.uz/articles/radiologiya/doppler-jigar
[21] Med1.uz. Jigar transplantatsiyasidan keyingi qon tomir asoratlari. Available from: https://med1.uz/articles/transplantologiya/qon-tomir-asoratlari
[22] Med1.uz. Jigar transplantatsiyasidan keyingi o't yo'llari asoratlari. Available from: https://med1.uz/articles/transplantologiya/ot-yollari
[23] Med1.uz. Kontrast kuchaytirilgan ultratovushning klinik ahamiyati. Available from: https://med1.uz/articles/radiologiya/ceus
[24] Med1.uz. Jigar transplantatsiyasi bemorlarini dinamik kuzatish. Available from: https://med1.uz/articles/transplantologiya/kuzatish
[25] Med1.uz. Jigar kasalliklarida ultratovush tekshiruvining zamonaviy imkoniyatlari. Available from: https://med1.uz/articles/radiologiya/ultratovush-jigar
[26] Med1.uz. Transplantatsiyadan keyingi bemorlarni instrumental monitoring qilish. Available from: https://med1.uz/articles/transplantologiya/instrumental-monitoring